Dr. Charlie Carmichael
Chief Executive Officer
LightEyez Limited
The News Building
3 London Bridge Street
London
SE1 9SG
United KingdomFEI 3027822577Issued Feb 15, 2024Center for Drug Evaluation and Research | CDER
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3027822577.
Violations1
Issue DateFeb 15, 2024
Product TypeDrugs
StatusOpen
Letter Details
Firm
LightEyez Limited
Location
Dr. Charlie Carmichael
Chief Executive Officer
LightEyez Limited
The News Building
3 London Bridge Street
London
SE1 9SG
United Kingdom
FEI Number
3027822577
Country
United Kingdom
Issue Date
February 15, 2024
Issuing Office
Center for Drug Evaluation and Research | CDER
Product Type
Drugs
Status
Open
Summary
LightEyez Limited was cited for manufacturing and distributing MSM Eye Repair Drops, an over-the-counter ophthalmic drug product that FDA testing confirmed was adulterated due to containing filthy, putrid, or decomposed substance. The company's manufacturing methods, facilities, and controls failed to comply with Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals under 21 CFR Parts 210 and 211. FDA had conducted a meeting with the company on August 24, 2023, and reviewed their subsequent correspondence, which did not adequately address the manufacturing deficiencies identified during testing.
LightEyez Limited FDA Warning Letter, February 15, 2024